M-Sympathol
Cognitive Disorder
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoSmall moleculePhase 2/3Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 95/ 100
Competitive context
132 Active assets in the Cognitive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nicotine University of Southern California | Phase 2 | BBB |
Oxybutynin University of Alberta | Phase 4 | BBB |
Quetiapine Emory University | Phase 4 | BB |
Rivastigmine VA Office of Research and Development | Phase 4 | BB |
Metformin Fudan University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
M-Sympathol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →